Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases
BOSTON--(BUSINESS WIRE)-- In a Phase I clinical trial, fourteen healthy volunteers were given a single dose of 1000mg CBD (5 ...